Please assess the completion status of the following clinical trial:

Trial Title: Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, advanced metastatic or recurrent clear cell cancer of the ovary~* At least one index lesion measuring 2 cm in diameter~* Must be able to provide written informed consent, and willing to comply with protocol procedures of the study~* Off all active therapy for at least 4 weeks (cytotoxic chemotherapy, radiation, immune therapy, hormone therapy, clinical trials or new agents)~Exclusion Criteria:~* Renal failure (eGFR \< 50mls/min)~* Patients with unknown primaries~* Previous history of cancer, except treated non-melanoma skin cancer, non-invasive breast cancer, non-invasive cervical cancer; or curatively treated solid cancer with no evidence of recurrence for more than 5 years.~* Receiving or had received active therapy in the form or chemotherapy or radiation within 4 weeks of the PET scan~* ECOG status ≥ 3~* Unable to tolerate a PET scan which involves an injection of radiopharmaceutical and lying flat and still for 30 minutes.~* Weight more than 204.5 kg (Physical Limitation of Imaging and Radiotherapy Couches) or cannot fit through the PET/CT machine (diameter 70cm).~* Patient is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).